Thrombotech Technologies Ltd. has obtained Ministry of Health approval to begin a Phase I human clinical trial of its stroke treatment, a peptide, THR-18, which is administered alongside existing stroke treatments. The trial will include 40 healthy volunteers to test the safety of THR-18 to enable...
FULL ARTICLE AT Globes Online